3KY Stock Overview
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Hansoh Pharmaceutical Group Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.16 |
| 52 Week High | HK$2.86 |
| 52 Week Low | HK$1.32 |
| Beta | 0.63 |
| 1 Month Change | 3.85% |
| 3 Month Change | -2.70% |
| 1 Year Change | n/a |
| 3 Year Change | 4.85% |
| 5 Year Change | -22.86% |
| Change since IPO | 15.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3KY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -2.6% |
| 1Y | n/a | -15.6% | 6.9% |
Return vs Industry: Insufficient data to determine how 3KY performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 3KY performed against the German Market.
Price Volatility
| 3KY volatility | |
|---|---|
| 3KY Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3KY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3KY's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 9,099 | Huijuan Zhong | www.hspharm.com |
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors.
Hansoh Pharmaceutical Group Company Limited Fundamentals Summary
| 3KY fundamental statistics | |
|---|---|
| Market cap | €13.12b |
| Earnings (TTM) | €619.24m |
| Revenue (TTM) | €1.59b |
21.2x
P/E Ratio8.3x
P/S RatioIs 3KY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3KY income statement (TTM) | |
|---|---|
| Revenue | CN¥12.10b |
| Cost of Revenue | CN¥1.09b |
| Gross Profit | CN¥11.01b |
| Other Expenses | CN¥6.30b |
| Earnings | CN¥4.71b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 91.01% |
| Net Profit Margin | 38.97% |
| Debt/Equity Ratio | 0.1% |
How did 3KY perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield40%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 07:41 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hansoh Pharmaceutical Group Company Limited is covered by 32 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sharon Shi | BOCI Research Ltd. |
| Bo Li | BofA Global Research |
| Jin Zhang | China International Capital Corporation Limited |